Cite
HARVARD Citation
Earl, H. et al. (n.d.). Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet oncology. 16 (6), pp. 656-666. [Online].